FDA Nears Decision on Celcuity Breast Cancer Drug That Could Reshape Treatment

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

This article is about advanced breast cancer, specifically the most common type that can stop responding to hormone therapy.

New option after hormone failure.Before, patients with advanced HR-positive, HER2-negative breast cancer had limited choices once their disease progressed past initial hormone therapy. Gedatolisib could provide a targeted alternative, potentially delaying further tumor growth.
Targets overactive PI3K enzyme.Many breast cancers grow because the PI3K enzyme is too active, and older treatments did not block this specific driver. Gedatolisib directly inhibits this enzyme, attacking the cancer at a molecular level rather than using a broad approach.
Potential blockbuster access.Because analysts predict this drug could become a blockbuster, it is more likely to be widely manufactured and distributed. This increases the chances that many patients, not just those in clinical trials, will gain access to it.
Could reshape standard treatment.If approved, gedatolisib would become a new pillar of care for the most common breast cancer subtype. This shifts the landscape from relying on older therapies to offering a modern, enzyme-specific treatment that may improve outcomes.

The U.S. Food and Drug Administration is expected to rule soon on a new breast cancer therapy that analysts say could become a blockbuster and potentially make its developer a prime acquisition target for larger pharmaceutical companies. Celcuity’s experimental treatment, gedatolisib, is under review for patients with advanced HR-positive, HER2-negative breast cancer, the most common form of the disease.

If approved, the drug would offer a new option for patients whose cancer has progressed after initial hormone therapy. Gedatolisib works by blocking a key enzyme called PI3K, which is often overactive in cancer cells, while also targeting mTOR, another protein involved in tumor growth. In a late-stage clinical trial, the combination of gedatolisib plus standard hormone therapy more than doubled the median time patients lived without their cancer worsening, from 7.3 months to 15.2 months, compared to hormone therapy alone.

That level of improvement has caught the attention of industry observers. Some analysts have projected peak annual sales for the drug could exceed $2 billion, making Celcuity an attractive partner or acquisition target for a larger pharmaceutical company looking to expand its oncology portfolio. The company’s CEO has stated that the drug’s potential “belongs in the hands” of a major player, though no deal has been announced.

What This Means for Patients

For the roughly 200,000 Americans diagnosed with HR-positive, HER2-negative breast cancer each year, treatment options have expanded significantly in the past decade. However, many patients eventually develop resistance to standard hormone therapies. Gedatolisib represents a novel approach because it attacks the cancer through two pathways at once, which may help overcome that resistance. The most common side effects in the trial included mouth sores, rash, and elevated blood sugar, which were generally manageable with supportive care.

The FDA is expected to make its decision by the end of the first quarter of 2025. If the agency grants approval, Celcuity will need to scale up manufacturing and launch the drug commercially. The company has already begun preparing for that possibility, building a sales team and supply chain. For patients and oncologists waiting for a new tool against advanced breast cancer, the coming months could bring a meaningful advance in care.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.